
- ONCOLOGY Vol 23 No 4
- Volume 23
- Issue 4
Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Maintenance rituximab (Rituxan) following CVP therapy (cyclophosphamide, vincristine, prednisone) improves progression-free survival in patients with stage III/IV indolent lymphoma, according to a phase III study published online ahead of print in the Journal of Clinical Oncology (March 2, 2009).
Maintenance rituximab (Rituxan) following CVP therapy (cyclophosphamide, vincristine, prednisone) improves progression-free survival in patients with stage III/IV indolent lymphoma, according to a phase III study published online ahead of print in the
Researchers looked at 311 patients with stable or responding disease after CVP therapy. At 2 years, an improved disease response was seen in 22% of rituximab-treated patients vs just 7% of control subjects. Toxic effects were minimal in both groups. Three-year progression-free survival was also higher in the maintenance rituximab group: 68% vs 33% in controls.
Articles in this issue
about 17 years ago
Everolimus Approved for Advanced Kidney Cancerabout 17 years ago
Report Shows Record Number of Cancer Drugs in Developmentabout 17 years ago
Black Cohosh (Cimicifuga racemosa)about 17 years ago
Clinical Trials and Radiation Oncology Technologiesabout 17 years ago
Health Literacy: Improving Patient UnderstandingRelated Content



93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer

























































